Quantification in molecular ultrasound imaging a comparative study in mice between healthy liver and a human hepatocellular carcinoma xenograft

Katsutoshi Sugimoto, Fuminori Moriyasu, Yoichi Negishi, Nobuhito Hamano, Hisashi Oshiro, Nicolas G. Rognin, Tetsuya Yoshida, Naohisa Kamiyama, Yukihiko Aramaki, Yasuharu Imai

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objectives-The purpose of this study was to quantitatively assess the contrast kinetics of vascular endothelial growth factor receptor 2 (VEGFR2)-targeted microbubbles (BR55; Bracco Suisse, Geneva, Switzerland) compared to clinically used microbubbles (SonoVue; Bracco SpA, Milan, Italy) in both normal liver and human hepatocellular carcinoma xenograft tumors in mice. Methods-Microbubbles were injected intravenously into healthy mice (n = 5) and mice bearing hepatocellular carcinoma xenograft tumors (n = 10). Cine loops of contrast enhancement in normal liver and the tumors were acquired for 10 minutes. Quantitative perfusion parameters were derived by fitting time-intensity curves using a dedicated mathematical model combining a bolus function and a ramp function. Immunohistochemical examinations were also performed for normal liver and tumor specimens to determine the level of VEGFR2 expression. Results-The peak contrast enhancement observed in normal liver with BR55 was comparable to that with SonoVue, whereas a significant difference was observed in latephase enhancement at 10 minutes (ramp slope: P<.01). In the tumor model, SonoVue was rapidly cleared from the circulation, without any noticeable binding in the tumor, whereas BR55 showed a gradual decline, resulting in a longer wash-out period (mean transit time: P <.01). Immunohistochemical examinations showed that intratumoral vascular endothelial cells had sparse and weak VEGFR2 expression, whereas the sinusoidal capillaries in normal liver had much more diffuse and much stronger expression. Conclusions-Our results suggest that BR55 accurately reflects the VEGFR2 status in human hepatocellular carcinoma xenograft tumors. We showed that quantification applied to molecular ultrasound imaging may provide an objective method for measuring the degree of microbubble binding.

Original languageEnglish
Pages (from-to)1909-1916
Number of pages8
JournalJournal of Ultrasound in Medicine
Volume31
Issue number12
Publication statusPublished - Dec 1 2012
Externally publishedYes

Fingerprint

Molecular Imaging
Heterografts
Hepatocellular Carcinoma
Ultrasonography
Microbubbles
Vascular Endothelial Growth Factor Receptor-2
Liver
Neoplasms
Architectural Accessibility
Switzerland
Italy
Theoretical Models
Endothelial Cells
Perfusion
contrast agent BR1

Keywords

  • Angiogenesis
  • BR55
  • Hepatocellular carcinoma
  • Molecular ultrasound
  • Vascular endothelial growth factor receptor 2

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology
  • Medicine(all)

Cite this

Sugimoto, K., Moriyasu, F., Negishi, Y., Hamano, N., Oshiro, H., Rognin, N. G., ... Imai, Y. (2012). Quantification in molecular ultrasound imaging a comparative study in mice between healthy liver and a human hepatocellular carcinoma xenograft. Journal of Ultrasound in Medicine, 31(12), 1909-1916.

Quantification in molecular ultrasound imaging a comparative study in mice between healthy liver and a human hepatocellular carcinoma xenograft. / Sugimoto, Katsutoshi; Moriyasu, Fuminori; Negishi, Yoichi; Hamano, Nobuhito; Oshiro, Hisashi; Rognin, Nicolas G.; Yoshida, Tetsuya; Kamiyama, Naohisa; Aramaki, Yukihiko; Imai, Yasuharu.

In: Journal of Ultrasound in Medicine, Vol. 31, No. 12, 01.12.2012, p. 1909-1916.

Research output: Contribution to journalArticle

Sugimoto, K, Moriyasu, F, Negishi, Y, Hamano, N, Oshiro, H, Rognin, NG, Yoshida, T, Kamiyama, N, Aramaki, Y & Imai, Y 2012, 'Quantification in molecular ultrasound imaging a comparative study in mice between healthy liver and a human hepatocellular carcinoma xenograft', Journal of Ultrasound in Medicine, vol. 31, no. 12, pp. 1909-1916.
Sugimoto, Katsutoshi ; Moriyasu, Fuminori ; Negishi, Yoichi ; Hamano, Nobuhito ; Oshiro, Hisashi ; Rognin, Nicolas G. ; Yoshida, Tetsuya ; Kamiyama, Naohisa ; Aramaki, Yukihiko ; Imai, Yasuharu. / Quantification in molecular ultrasound imaging a comparative study in mice between healthy liver and a human hepatocellular carcinoma xenograft. In: Journal of Ultrasound in Medicine. 2012 ; Vol. 31, No. 12. pp. 1909-1916.
@article{5e068348671c4eb6967249f17eaebff7,
title = "Quantification in molecular ultrasound imaging a comparative study in mice between healthy liver and a human hepatocellular carcinoma xenograft",
abstract = "Objectives-The purpose of this study was to quantitatively assess the contrast kinetics of vascular endothelial growth factor receptor 2 (VEGFR2)-targeted microbubbles (BR55; Bracco Suisse, Geneva, Switzerland) compared to clinically used microbubbles (SonoVue; Bracco SpA, Milan, Italy) in both normal liver and human hepatocellular carcinoma xenograft tumors in mice. Methods-Microbubbles were injected intravenously into healthy mice (n = 5) and mice bearing hepatocellular carcinoma xenograft tumors (n = 10). Cine loops of contrast enhancement in normal liver and the tumors were acquired for 10 minutes. Quantitative perfusion parameters were derived by fitting time-intensity curves using a dedicated mathematical model combining a bolus function and a ramp function. Immunohistochemical examinations were also performed for normal liver and tumor specimens to determine the level of VEGFR2 expression. Results-The peak contrast enhancement observed in normal liver with BR55 was comparable to that with SonoVue, whereas a significant difference was observed in latephase enhancement at 10 minutes (ramp slope: P<.01). In the tumor model, SonoVue was rapidly cleared from the circulation, without any noticeable binding in the tumor, whereas BR55 showed a gradual decline, resulting in a longer wash-out period (mean transit time: P <.01). Immunohistochemical examinations showed that intratumoral vascular endothelial cells had sparse and weak VEGFR2 expression, whereas the sinusoidal capillaries in normal liver had much more diffuse and much stronger expression. Conclusions-Our results suggest that BR55 accurately reflects the VEGFR2 status in human hepatocellular carcinoma xenograft tumors. We showed that quantification applied to molecular ultrasound imaging may provide an objective method for measuring the degree of microbubble binding.",
keywords = "Angiogenesis, BR55, Hepatocellular carcinoma, Molecular ultrasound, Vascular endothelial growth factor receptor 2",
author = "Katsutoshi Sugimoto and Fuminori Moriyasu and Yoichi Negishi and Nobuhito Hamano and Hisashi Oshiro and Rognin, {Nicolas G.} and Tetsuya Yoshida and Naohisa Kamiyama and Yukihiko Aramaki and Yasuharu Imai",
year = "2012",
month = "12",
day = "1",
language = "English",
volume = "31",
pages = "1909--1916",
journal = "Journal of Ultrasound in Medicine",
issn = "0278-4297",
publisher = "American Institute of Ultrasound in Medicine",
number = "12",

}

TY - JOUR

T1 - Quantification in molecular ultrasound imaging a comparative study in mice between healthy liver and a human hepatocellular carcinoma xenograft

AU - Sugimoto, Katsutoshi

AU - Moriyasu, Fuminori

AU - Negishi, Yoichi

AU - Hamano, Nobuhito

AU - Oshiro, Hisashi

AU - Rognin, Nicolas G.

AU - Yoshida, Tetsuya

AU - Kamiyama, Naohisa

AU - Aramaki, Yukihiko

AU - Imai, Yasuharu

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Objectives-The purpose of this study was to quantitatively assess the contrast kinetics of vascular endothelial growth factor receptor 2 (VEGFR2)-targeted microbubbles (BR55; Bracco Suisse, Geneva, Switzerland) compared to clinically used microbubbles (SonoVue; Bracco SpA, Milan, Italy) in both normal liver and human hepatocellular carcinoma xenograft tumors in mice. Methods-Microbubbles were injected intravenously into healthy mice (n = 5) and mice bearing hepatocellular carcinoma xenograft tumors (n = 10). Cine loops of contrast enhancement in normal liver and the tumors were acquired for 10 minutes. Quantitative perfusion parameters were derived by fitting time-intensity curves using a dedicated mathematical model combining a bolus function and a ramp function. Immunohistochemical examinations were also performed for normal liver and tumor specimens to determine the level of VEGFR2 expression. Results-The peak contrast enhancement observed in normal liver with BR55 was comparable to that with SonoVue, whereas a significant difference was observed in latephase enhancement at 10 minutes (ramp slope: P<.01). In the tumor model, SonoVue was rapidly cleared from the circulation, without any noticeable binding in the tumor, whereas BR55 showed a gradual decline, resulting in a longer wash-out period (mean transit time: P <.01). Immunohistochemical examinations showed that intratumoral vascular endothelial cells had sparse and weak VEGFR2 expression, whereas the sinusoidal capillaries in normal liver had much more diffuse and much stronger expression. Conclusions-Our results suggest that BR55 accurately reflects the VEGFR2 status in human hepatocellular carcinoma xenograft tumors. We showed that quantification applied to molecular ultrasound imaging may provide an objective method for measuring the degree of microbubble binding.

AB - Objectives-The purpose of this study was to quantitatively assess the contrast kinetics of vascular endothelial growth factor receptor 2 (VEGFR2)-targeted microbubbles (BR55; Bracco Suisse, Geneva, Switzerland) compared to clinically used microbubbles (SonoVue; Bracco SpA, Milan, Italy) in both normal liver and human hepatocellular carcinoma xenograft tumors in mice. Methods-Microbubbles were injected intravenously into healthy mice (n = 5) and mice bearing hepatocellular carcinoma xenograft tumors (n = 10). Cine loops of contrast enhancement in normal liver and the tumors were acquired for 10 minutes. Quantitative perfusion parameters were derived by fitting time-intensity curves using a dedicated mathematical model combining a bolus function and a ramp function. Immunohistochemical examinations were also performed for normal liver and tumor specimens to determine the level of VEGFR2 expression. Results-The peak contrast enhancement observed in normal liver with BR55 was comparable to that with SonoVue, whereas a significant difference was observed in latephase enhancement at 10 minutes (ramp slope: P<.01). In the tumor model, SonoVue was rapidly cleared from the circulation, without any noticeable binding in the tumor, whereas BR55 showed a gradual decline, resulting in a longer wash-out period (mean transit time: P <.01). Immunohistochemical examinations showed that intratumoral vascular endothelial cells had sparse and weak VEGFR2 expression, whereas the sinusoidal capillaries in normal liver had much more diffuse and much stronger expression. Conclusions-Our results suggest that BR55 accurately reflects the VEGFR2 status in human hepatocellular carcinoma xenograft tumors. We showed that quantification applied to molecular ultrasound imaging may provide an objective method for measuring the degree of microbubble binding.

KW - Angiogenesis

KW - BR55

KW - Hepatocellular carcinoma

KW - Molecular ultrasound

KW - Vascular endothelial growth factor receptor 2

UR - http://www.scopus.com/inward/record.url?scp=84871821612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871821612&partnerID=8YFLogxK

M3 - Article

VL - 31

SP - 1909

EP - 1916

JO - Journal of Ultrasound in Medicine

JF - Journal of Ultrasound in Medicine

SN - 0278-4297

IS - 12

ER -